Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor
— Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor
July 22, 2026
• 2 min read
The FDA approved zidesamtinib (Jideytro) for previously treated adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), drugmaker GSK announced Wednesday.
Zidesamtinib is a next-generation, brain-penetrant ROS1-selective inhibitor designed to overcome ROS1 resistance mutations.
The FDA has approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung…
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products…
Upfront treatment options set to expand for NSCLC patients with EGFR exon 20 insertions
The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive…
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO…
